$80.36
2.92% yesterday
Nasdaq, Dec 24, 10:40 pm CET
ISIN
US45720L1070
Symbol
INBX

Inhibrx Inc Stock price

$80.36
-0.65 0.80% 1M
+65.60 444.44% 6M
+64.96 421.82% YTD
+65.87 454.59% 1Y
+58.43 266.51% 3Y
+41.21 105.26% 5Y
+62.13 340.77% 10Y
+62.13 340.77% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+2.28 2.92%
ISIN
US45720L1070
Symbol
INBX
Industry

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$1.1b
Net debt
positive
Cash
$153.1m
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
834.8 | 881.4
EV/Sales
796.8 | 841.3
EV/FCF
negative
P/B
31.7
Financial Health
Equity Ratio
74.0%
Return on Equity
1,259.4%
ROCE
-78.5%
ROIC
-
Debt/Equity
2.7
Financials (TTM | estimate)
Revenue
$1.4m | $1.3m
EBITDA
$-109.2m | -
EBIT
$-111.1m | $-131.1m
Net Income
$-111.8m | -
Free Cash Flow
$-143.4m
Growth (TTM | estimate)
Revenue
-19.1% | 563.0%
EBITDA
70.3% | -
EBIT
69.9% | 60.5%
Net Income
-106.8% | -
Free Cash Flow
32.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-7,799.7% | -
EBIT
-7,937.8%
Net
-7,983.9% | -
Free Cash Flow
-10,245.6%
More
EPS
$-7.2
FCF per Share
-
Short interest
6.9%
Employees
169
Rev per Employee
$0.0
Show more

Is Inhibrx Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Inhibrx Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Inhibrx Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Inhibrx Inc forecast:

Hold
50%
Sell
50%

Financial data from Inhibrx Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1.40 1.40
19% 19%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 28 28
76% 76%
2,013%
- Research and Development Expense 82 82
67% 67%
5,887%
-109 -109
70% 70%
-7,800%
- Depreciation and Amortization 1.93 1.93
2% 2%
138%
EBIT (Operating Income) EBIT -111 -111
70% 70%
-7,938%
Net Profit -112 -112
107% 107%
-7,984%

In millions USD.

Don't miss a Thing! We will send you all news about Inhibrx Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inhibrx Inc Stock News

Neutral
PRNewsWire
9 days ago
SAN DIEGO , Dec. 16, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/3 clinical trial in combination with Keytruda® (pembrolizumab) as a first-line treatment for patients with locally advanced unresectable or me...
Neutral
PRNewsWire
about one month ago
SAN DIEGO , Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter of 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.
Neutral
PRNewsWire
about 2 months ago
SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences: 21st Annual Industry/Academia Precision Oncology & Radmed Symposium November 5 th, 2025 – La Jol...
More Inhibrx Inc News

Company Profile

Inhibrx, Inc. engages in researching and developing biotechnology. It is a clinical stage company, which focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.

Head office United States
CEO Mark Lappe
Employees 169
Founded 2010
Website inhibrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today